<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03998657</url>
  </required_header>
  <id_info>
    <org_study_id>PCa003CA</org_study_id>
    <nct_id>NCT03998657</nct_id>
  </id_info>
  <brief_title>Continued Access of Focal MR-Guided Focused Ultrasound for Localized Intermediate Risk Prostate Lesions</brief_title>
  <official_title>A Continued Access Study to Evaluate Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This extended clinical investigation is a multicenter, prospective, sing arm study intended
      to provide continued access of the Exablate(R) Model 2100 device (Exablate Prostate) to
      patients for treatment of prostate lesions and collect additional safety and effectiveness
      data during the 510(k) preparation and review period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of device/procedure-related complications following treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Safety will be evaluated by incidence and severity of device/procedure-related complications following treatment. Adverse events will be recorded and categorized according to severity and relationship to the biopsy procedure, the Exablate procedure, or to the Exablate device. They will be classified based on body system, severity, and frequency.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportions of treated subjects reporting negative Gleason 7 biopsy within the prostate biopsy treatment area.</measure>
    <time_frame>6 months</time_frame>
    <description>Effectiveness will be evaluated by targeted lesion control based on biopsy results. Proportions of treated subjects reporting negative Gleason 7 biopsy within the treatment area and/or MRI verification of index lesion(s) ablation. PSA results and validated subject-reported questionnaires will be summarized.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Exablate Treated Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Exablate Prostate 2100 Type-3 System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Exablate Prostate Treatment</intervention_name>
    <description>The Exablate system is a non-invasive thermal ablation device that is being used to ablate tissue. The system combines a focused ultrasound surgery (FUS) delivery system and MRI scanner.</description>
    <arm_group_label>Exablate Treated Arm</arm_group_label>
    <other_name>Exablate Prostate</other_name>
    <other_name>Exablate MRgFUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven adenocarcinoma of the prostate

          -  Intermediate risk, organ-confined prostate cancer (T1a up to T2b) and voluntarily
             chooses Exablate, who may currently be on watchful waiting or active surveillance and
             not in need of imminent radical therapy

          -  Up to 2 MRI visible Gleason 7 confirmed on mapping prostate biopsy that Investigator
             deems treatable within a single treatment session; may have secondary Gleason 6 on
             ipsilateral or contralateral side confirmed with biopsy and/or MRI

          -  PSA less than or equal to 20ng/mL

        Exclusion Criteria:

          -  Evidence of distant prostate cancer including lymph node involvement and/or metastasis
             of cancer

          -  Subject undergoing androgen deprivation therapy, initiating any new medication that
             can affect PSA, or history of bilateral orchiectomy

          -  Active bladder cancer, active UTI, or untreated prostatitis

          -  Untreated urethral stricture/bladder neck contracture

          -  Prostate-specific chemotherapy, brachytherapy, cryotherapy, photodynamic therapy,
             radical prostatectomy, or focal therapy (excluding FUS); or any prior radiation
             therapy to the pelvis for prostate cancer or any other malignancy

          -  Subjects with pathology or implants that may adversely impact treatment due to
             acoustics, imaging, or safe probe insertion

          -  Subject not able or willing to tolerate the required prolonged stationary supine
             position during treatment

          -  Contraindications to MRI
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Males only</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ned Realiza</last_name>
      <phone>650-498-8496</phone>
      <email>nrealiza@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Sonn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sperling Prostate Center</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lillian Blanchard</last_name>
      <phone>561-300-1353</phone>
      <email>lillianb@sperlingmedical.com</email>
    </contact>
    <contact_backup>
      <last_name>Jackie Stumpf</last_name>
      <phone>561-300-1363</phone>
      <email>jstumpf@sperlingmedical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dan Sperling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wesley Want</last_name>
      <phone>617-525-6360</phone>
      <email>wcwang@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Clare Tempany, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Jennison</last_name>
      <phone>507-293-0988</phone>
      <email>jennison.shirley@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>David Woodrum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lance Mynderse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Tatge</last_name>
      <phone>646-227-2257</phone>
      <email>tatger@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Behfar Ehdaie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

